Presenting Author: Jordana GA Coelho-dos-Reis
, Dr at Univ. Fed. de Minas Gerais
Abstract:
Herein, the impact of BromAc on the SARS-CoV-2-specific inflammatory response was evaluated. A reduction of the cytokine storm, composed of chemokines, growth factors, proinflammatory and regulatory cytokines produced after short-term in vitro culture with the inactivated virus (iSARS-CoV-2). The immunophenotypic analysis showed that BromAc was able to downmodulate CD16+ neutrophils and CD14+ monocytes observed after stimulation with iSARS-CoV-2. Conversely, BromAc treatment increased steady-state HLA-DR expression in CD14+ monocytes and preserved this activation marker in this subset upon iSARS-CoV-2 stimuli, indicating improved monocyte activation upon BromAc treatment. Additionally, BromAc downmodulated the iSARS-CoV-2-induced production of TNF-α by the CD19+ B-cells. System biology approaches, utilizing comprehensive correlation matrices and networks show distinct patterns of connectivity in groups treated with BromAc, suggesting loss of connections promoted by the compound and by iSARS-CoV-2 stimuli. In addition, BromAc seems to disengage proinflammatory responses and their interactions with other soluble factors and axis orchestrated by SARS-CoV-2. These results give new insights on the mechanisms for the robust anti-inflammatory effect of BromAc in the steady state as well SARS-CoV-2-specific immune leukocyte responses, indicating its potential as a therapeutic strategy for COVID-19.
Harnessing a potent combination to address a pandemic virus: SARS-CoV-2-specific antiviral and anti-inflammatory activity of BromAc
Category
Late Breaking Abstracts
Description
Custom CSS
double-click to edit, do not edit in source
Date: May 4 Presentation Time: 03:15 PM to 04:30 PM Room: Exhibit Hall F1